SpotDraft, an AI-driven contract lifecycle management (CLM) platform for in-house legal teams, raised $54 million in Series B funding led by Vert ...

Beyond computer science laboratories and the big Silicon Valley companies, artificial intelligence is now becoming more ...

ICER's evaluation of Vertex Pharmaceuticals' non-opioid pain drug, Journavx, finds cost-effectiveness related to potential ...

Despite a $400 million impairment charge, analysts say the removal of a drug-device combo from its portfolio is not a huge ...

CHATHAM, NJ / ACCESS Newswire / March 31, 2025 / This post was written and published as a collaboration between the in-house ...

The equity portion of the Abrdn Healthcare Investors Fund fell (gross of fees) but outperformed its custom benchmark over the ...

Vertex Pharmaceuticals (NasdaqGS:VRTX) saw a notable 20.53% share price increase over the last quarter, which coincided with several key developments in its Type 1 Diabetes (T1D) initiatives. The ...

We recently published a list of 20 Most Expensive Stocks Insiders Are Dumping In March. In this article, we are going to take ...

Siemens Healthineers announced today its Innovance Antithrombin assay has achieved FDA clearance for a new claim allowing it to be used as a companion diagnostic test for people receiving treatment ...

With President Donald Trump expected to levy tariffs on pharmaceuticals manufactured outside the United States, industry ...

Inc. ("bluebird") today confirmed it has received an unsolicited non-binding written proposal (the "Ayrmid Proposal") from Ayrmid Ltd ("Ayrmid") to acquire bluebird for an upfront cash payment of ...

According to a Vertex spokesperson, the drug is seeing strong initial market adoption, with growing payer coverage and ...